Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL442 in Cutaneous Squamous Cell Carcinoma in Situ
NCT03333694Phase 1Terminated
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in cutaneous squamous cell carcinoma in situ (SCCIS) comparing CLL442 with Placebo (2 arms). Primary endpoints: Incidence of adverse events (AE), serious adverse events (SAEs) of CLL442 on lesion free skin at Day 7, Change in the size of One SCCis lesion area at Day 84 and 2 more. Started Dec 2017; status: terminated.
02
Drugs
CLL442
03
Conditions
cutaneous squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on NCT03333694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333694.